leakadine and Skin-Neoplasms

Changes in the immunologic parameters of 39 patients with Kaposi's sarcoma over the course of leakadin therapy were under study, i. e. total leukocyte and lymphocyte counts, immunoregulatory cells in spontaneous and complementary rosette formation, and in that with monoclonal antibodies. The therapeutic efficacies and immunostimulating activities of prospidin and leakadin, a new Soviet drug, are compared. Besides sufficient therapeutic efficacy, leakadin has shown a manifest immunocorrective effect, increasing the counts of CD2+ and CD3+ cells, i. e. of the total T-lymphocyte pool (including the "young" cells) and, consequently, of its mature fraction, CD4+ and theophyllin-resistant T-lymphocytes, CD8+ cells; this fact recommends the drug for the treatment of patients with Kaposi's sarcoma. Since the immunomodulating effects of prospidin and leakadin are ambiguous, their combinations are advised for the treatment of Kaposi's sarcoma.

Topics: Adjuvants, Immunologic; Antigens, CD; Antineoplastic Agents; Aziridines; Drug Evaluation; HIV Antibodies; Humans; Immunity, Cellular; Leukocyte Count; Prospidium; Sarcoma, Kaposi; Skin Neoplasms